Johan Skog, PhD, has a background in gene therapy from Umea University, Sweden, where he did his PhD. He later moved to Boston and served as junior faculty at Massachusetts General Hospital (MGH)/Harvard Medical School, studying RNA profiles in tumor stem cells. During this time, he found that primary tumors shed microvesicles/exosomes containing RNA, leading to the first study showing mutational profiling of brain tumors through serum microvesicles. He was the primary inventor on the exosome/microvesicle technology that was patented through MGH and was later licensed to the company Exosome Diagnostics. Dr Skog now serves as the Chief Scientific Officer at Exosome Diagnostics, where he develops biofluid diagnostics in urine, blood and cerebrospinal fluid. The company has a clinical laboratory (CLIA approved) in St Paul, Minnesota, where the clinical studies are being performed, and a next generation sequencing/bioinformatics laboratory in Munich, Germany for research and development.